Trial reportSignal transduction and targeted therapy2026
Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01): a phase II clinical trial.
Trial report in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiation oncology at a new frontier: Hotspots, challenges, and emerging advances.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Patients diagnosed with limited-stage small cell lung cancer (LS-SCLC) face dismal long-term outcomes, as relapse occurs frequently even after standard concurrent chemoradiotherapy. Integrating immune checkpoint blockade into chemoradiotherapy regimens may enhance sustained disease control, yet prospective evidence for this strategy in LS-SCLC remains sparse. In this single-arm phase II study, we investigated sintilimab in combination with concurrent chemoradiotherapy (CCRT) among LS-SCLC patients who had favorable functional status. Twenty-two histologically verified LS-SCLC patients were treated with four 3-weekly cycles of chemotherapy alongside sintilimab, with concurrent thoracic radiation (45 Gy delivered in 30 fractions). The primary endpoint was progression-free survival (PFS). After a median follow-up of 44.7 months, the median PFS reached 29.6 months, with 12- and 24-month PFS rates of 72.7% and 54.5%, respectively. Median overall survival (OS) stood at 40.6 months, and the corresponding 12- and 24-month OS rates were 95.5% and 72.7%, respectively. An objective response rate (ORR) of 95.5% was observed. Most grade 3-4 adverse events were hematologic in nature, particularly neutropenia and thrombocytopenia. Three patients developed pneumonitis, one of whom had grade 2 or higher. No deaths attributable to treatment occurred. Elevated human leukocyte antigen class I (HLA-I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.